Home › Compound Library › Fluconazole

Fluconazole

Antibioticprescriptionoral · inferred

Triazole antifungal active against Candida and Cryptococcus species via inhibition of fungal 14-alpha-demethylase. Outstanding oral bioavailability (~90%), excellent CSF penetration, and a long 30-hour half-life support once-daily or single-dose regimens. Typical 100-400 mg daily; 150 mg single dose standard for uncomplicated vulvovaginal candidiasis.

Projected serum levels — 200 mg, once daily

Fluconazole
Fluconazole modeled serum levels, 200 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 3 days. 0 125 250 375 500 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 3
Fluconazole modeled serum levels with a loading dose of 461 mg, then 200 mg once daily The first dose is larger so levels approach steady state faster. 0 125 250 375 500 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 200 mg once daily (oral).

Loading schedule: 461 mg on day 1, then 200 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~3 days: peak ≈ 401 mg, trough ≈ 235 mg body load. Population-based estimate over 15 days for a 200 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antibiotic
Route modeled
Oral
Model confidence
inferred
Half-life
30 h
Common dose
200 mg
Suggested maximum
800 mg/day
Reference dose range
100–800 mg (single dose)
Suggested cadence
once daily
Validated against
200 mg oral — Cmax 4.5 mg/L at 1.5 h

Documented interactions

  • danger
    7-Hydroxymitragynine (7-OH) + Fluconazole CYP inhibition

    Fluconazole reversible_inhibitor of CYP3A4 predicted to change 7-Hydroxymitragynine (7-OH) AUC by ~2.20x

  • danger
    Alfuzosin (Uroxatral) + Fluconazole CYP inhibition

    Fluconazole reversible_inhibitor of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~3.33x

  • danger
    Alprazolam (Xanax) + Fluconazole CYP inhibition

    Fluconazole reversible_inhibitor of CYP3A4 predicted to change Alprazolam (Xanax) AUC by ~3.33x

  • danger
    Amlodipine (Norvasc) + Fluconazole CYP inhibition

    Fluconazole reversible_inhibitor of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~3.33x

  • danger
    Anastrozole (Arimidex) + Fluconazole CYP inhibition

    Fluconazole reversible_inhibitor of CYP3A4 predicted to change Anastrozole (Arimidex) AUC by ~2.68x

  • danger
    Astaxanthin + Fluconazole CYP inhibition

    Fluconazole reversible_inhibitor of CYP3A4 predicted to change Astaxanthin AUC by ~3.33x

Serum checks 247 modeled interaction pairings for fluconazole across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America Pappas PG et al. · Clinical Infectious Diseases, 2016 DOI

    IDSA guidelines establishing fluconazole as first-line therapy for many invasive and mucosal candidiasis syndromes, with specific dose recommendations based on site of infection and species.

  2. Pharmacokinetics of fluconazole in normal volunteers: single and multiple doses Shiba K, Saito A, Miyahara T · Antimicrobial Agents and Chemotherapy, 1990 DOI

    PK study in healthy volunteers established fluconazole's linear kinetics, ~90% bioavailability, 27-37 hour half-life, and predominantly renal elimination as unchanged drug.

  3. Azole antifungal agents, emphasis on new triazoles Como JA, Dismukes WE · New England Journal of Medicine, 1994 DOI

    Seminal NEJM review characterizing fluconazole's PK, spectrum, clinical efficacy across mucosal and invasive Candida infections, and cryptococcal meningitis.

3 published studies referenced in the app, each with a plain-language summary.